Newsroom

TORONTO--(BUSINESS WIRE)--Cizzle Brands Corporation (Cboe Canada: CZZL; OTCQB: CZZLF; Frankfurt: 8YF) (“Cizzle Brands” or the “Company”), the vertically integrated sports nutrition company that is elevating the game in health and wellness, today announced that CWENCH Hydration™ is now available at more than 170 Save-On-Foods locations across Western Canada. At launch, Save-On-Foods will be carrying an assortment of three of CWENCH Hydration’s most popular ready-to-drink (“RTD”) flavours – Blue...

IRVINE, Californie--(BUSINESS WIRE)--SBC Medical Group Holdings Incorporated (Nasdaq : SBC) (« SBC Medical » ou la « société »), une organisation de services médicaux fournissant un soutien en matière de gestion dans un large éventail de domaines de la santé, a annoncé aujourd’hui ses résultats financiers pour le trimestre clos le 31 mars 2026. Chiffres du premier trimestre 2026 Le chiffre d’affaires total s’est élevé à 43 millions de dollars, soit une baisse de 9 % d’une année sur l’autre. Le...

VICTORIA, British Columbia--(BUSINESS WIRE)--Vecima will highlight its leadership at ANGA COM 2026, showcasing AI-powered network operations, cloud-native DOCSIS 4.0 access, and fiber solutions....

TOKYO--(BUSINESS WIRE)--  Meiji Seika Pharma : résultats positifs de l’essai de phase III Integral-1 sur le nacubactam, un nouvel inhibiteur de β-lactamase, dans le traitement des infections compliquées des voies urinaires ou de la pyélonéphrite aiguë non compliquée ― Publiés dans The Lancet Meiji Seika Pharma Co., Ltd. (siège social à Tokyo ; président-directeur général : Toshiaki Nagasato) a annoncé aujourd’hui que les résultats de l’étude Integral-1, l’un des deux essais cliniques mondiaux d...

TURIN, Italy--(BUSINESS WIRE)--Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2026. Since the beginning of the year, the Group has recorded a consolidated revenues amounting to €645.0 million, an increase of 6.2% compared to the corresponding data for 2025. All indicators are positive for the period. In the first quarter of 2026 the consolidated EBITDA stood at €112.0 million compared to €105.3 million in 2025, equal to 17.4% of the turnover....

TURIN, Italien--(BUSINESS WIRE)--Der Verwaltungsrat der Reply S.p.A. [EXM, STAR: REY] hat heute die Ergebnisse zum 31. März 2026 genehmigt. Seit Beginn des Jahres verzeichnete die Gruppe einen Konzernumsatz von 645,0 Millionen Euro – dies entspricht einer Steigerung von 6,2% gegenüber dem Vergleichszeitraum 2025. Alle Kennzahlen des Berichtszeitraums waren positiv. Im ersten Quartal 2026 betrug das konsolidierte EBITDA 112,0 Millionen Euro im Vergleich zu 105,3 Mio. im Jahr 2025 und entspricht...

TORINO, Italia--(BUSINESS WIRE)--Il Consiglio di Amministrazione di Reply S.p.A. [EXM, STAR: REY] ha approvato oggi i risultati al 31 marzo 2026. Da inizio anno, il Gruppo ha registrato ricavi consolidati pari a 645,0 milioni di euro, in incremento del 6,2% rispetto al corrispondente periodo del 2025. Positivi tutti gli indicatori del periodo. Nel primo trimestre 2026 l’EBITDA consolidato è stato pari a 112,0 milioni di euro rispetto ai 105,3 milioni di euro registrati nel 2025 ed è pari al 17,...

TOKYO--(BUSINESS WIRE)--  Meiji Seika Pharma: risultati positivi da Integral-1, lo studio clinico di fase III su nacubactam, un nuovo inibitore delle β-lattamasi, nel trattamento delle infezioni del tratto urinario complicate o nella pielonefrite acuta non complicata, pubblicati in The Lancet Meiji Seika Pharma Co., Ltd. (con sede a Tokyo; Presidente e Direttore rappresentante: Toshiaki Nagasato) oggi ha annunciato che i risultati dello studio Integral-1, uno di due studi clinici globali di fas...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 14.05.2026 FTFX IE00BD5HBQ97   63,402.00 USD   1,691,529.99   26.679  ...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to present 8 abstracts on affordability, access and adoption across women’s health, biosimilar and general medicines portfolio at ISPOR 2026....